Araucaria heterophylla oleogum resin essential oil is a novel aldose reductase and butyryl choline esterase enzymes inhibitor: in vitro and in silico evidence.

Publication date: Jul 15, 2023

The essential oil isolated by hydrodistillation of the oleogum resin of Araucaria heterophylla has been analyzed by GC-MS. Twenty-four components accounting to 99. 89% of the total detected constituents of this essential oil were identified. The major ones were: caryophyllene oxide (14. 8%), ( +)-sabinene (12. 07%), D-limonene (11. 22%), caryophyllene (10. 36%), α-copaene (8. 00%), β-pinene (6. 44%), trans-verbenol (5. 88%) and α-pinene oxide (5. 18%). The in vitro inhibitory activities of this oil against aldose reductase, BuCHE, COX-2 and SARS-CoV-2 M enzymes were evaluated. This revealed promising inhibitory activity of the essential oil against both aldose reductase and BuCHE enzymes. The molecular docking study of the major components of the Araucaria heterophylla essential oil was carried out to correlate their binding modes and affinities for aldose reductase and BuCHE enzymes with the in vitro results. In conclusion, the in vitro inhibitory activity of the essential oil attributed to the synergistic effect between its components and the in silico study suggested that compounds containing epoxide and hydroxyl groups may be responsible for this activity. This study is preliminary screening for the oil to be used as antidiabetic cataract and Alzheimer’s disease therapeutics and further investigations may be required.

Open Access PDF

Concepts Keywords
Alzheimer Activity
Caryophyllene Aldose
Enzymes Araucaria
Oil Buche


Type Source Name
drug DRUGBANK Choline
drug DRUGBANK (4R)-limonene
disease MESH cataract
drug DRUGBANK Coenzyme M
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Sorbitol
disease MESH hyperglycemia
disease VO organ
disease MESH complications
drug DRUGBANK Acetylcholine
drug DRUGBANK Arachidonic Acid
disease MESH inflammation
drug DRUGBANK Chymotrypsin
disease IDO replication
drug DRUGBANK Papain
disease VO effective
disease MESH COVID 19
drug DRUGBANK Ethanol
drug DRUGBANK Rivastigmine
drug DRUGBANK Celecoxib
drug DRUGBANK Tipranavir
disease IDO site
disease VO time
drug DRUGBANK Water
drug DRUGBANK Amino acids
drug DRUGBANK Sodium sulfate
disease VO injection
drug DRUGBANK Helium
disease VO volume
disease VO USA
disease IDO assay
drug DRUGBANK Chloride ion
drug DRUGBANK Butyric Acid
drug DRUGBANK Prostaglandin G2
disease VO ANOVA
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Flunarizine
drug DRUGBANK Exisulind
drug DRUGBANK Tacrine
disease MESH oxidative stress
drug DRUGBANK Uracil
drug DRUGBANK Propylthiouracil
disease MESH tumor
drug DRUGBANK Trestolone
disease MESH Carcinogenesis
drug DRUGBANK Sulindac
disease MESH respiratory infections
drug DRUGBANK Ginsenosides
disease IDO process

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *